The findings were presented by Dr. Joseph Lombardi at the 37th annual VEITHsymposium. The trial is the first and only one of its kind to focus on a device uniquely designed for the endovascular treatment of Type B aortic dissection. The system as a whole is an investigational device not available in the United States.
Cooper University Hospital will take part in a clinical trial of the first medical device designed to specifically treat aortic dissections, an often-fatal condition that affects tens of thousands in the U.S. and claimed the life of actor John Ritter. Recognized as a preferred treatment center for the minimally invasive treatment of aortic diseases, Cooper was approved by the hospital’s institutional review board (IRB) for its involvement in the study. This approval follows the recent appointment of the trial’s global principal investigator, Joseph V. Lombardi, M.D., FACS, as chief of vascular and endovascular surgery at Cooper and associate professor of surgery at the Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey.
(Camden, New Jersey) Joseph V. Lombardi, M.D., joins the Department of Surgery at Cooper as the new Head of Vascular Surgery. He is a prominent vascular surgeon with expertise in minimally invasive endovascular therapy. Dr. Lombardi, is pioneering the treatment of thoracic aortic dissection with endovascular grafts and stents. He serves as Global Principal Investigator for the STABLE trial, investigating the use of endovascular therapy to treat complicated Type B Thoracic Aortic Dissection. “We are developing a masterful team of experts in surgery and Dr. Lombardi brings a talent unseen in our region,” said Jeffrey Carpenter, M.D., Chief of the Department of Surgery at Cooper.